Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany
Crystal Watson,1 Christine Prosser,2 Sebastian Braun,2 Pamela B Landsman-Blumberg,3 Erika Gleissner,4 Sarah Naoshy1 1Health Economics and Outcomes Research, Global Market Access, Biogen, Cambridge, MA, USA; 2Real World Evidence, Xcenda GmbH, Hanover, Germany; 3Applied Data Analytics, Xcenda LLC, Pal...
Main Authors: | Watson C, Prosser C, Braun S, Landsman-Blumberg PB, Gleissner E, Naoshy S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-02-01
|
Series: | ClinicoEconomics and Outcomes Research |
Subjects: | |
Online Access: | https://www.dovepress.com/germany-health-care-resource-utilization-before-and-after-nataliz-peer-reviewed-article-CEOR |
Similar Items
-
Rapid Progression of Low-Grade Cervical Dysplasia into Invasive Cancer during Natalizumab Treatment for Relapsing Remitting Multiple Sclerosis
by: King Man Wan, et al.
Published: (2019-01-01) -
Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
by: Mansour A. Alharbi, et al.
Published: (2023-05-01) -
Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
by: Takahiko Saida, et al.
Published: (2023-08-01) -
A COMPARATIVE ANALYSIS OF EFFICACY OF INTERFERON BETA 1-B AND NATALIZUMAB TREATMENT IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
by: T. I. Yakushina, et al.
Published: (2016-07-01) -
Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center
by: Marina Boziki, et al.
Published: (2021-08-01)